Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Mangoceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jacob Cohen

İcra Kurulu Başkanı

US$640.2k

Toplam tazminat

CEO maaş yüzdesi	40.6%
CEO görev süresi	3yrs
CEO sahipliği	30.3%
Yönetim ortalama görev süresi	2yrs
Yönetim Kurulu ortalama görev süresi	2yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Jacob Cohen'un ücretlendirmesi Mangoceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$9m
Mar 31 2024	n/a	n/a	-US$9m
Dec 31 2023	US$640k	US$260k	-US$9m
Sep 30 2023	n/a	n/a	-US$7m
Jun 30 2023	n/a	n/a	-US$6m
Mar 31 2023	n/a	n/a	-US$5m
Dec 31 2022	US$633k	US$70k	-US$2m

Tazminat ve Piyasa: Jacob 'ın toplam tazminatı ($USD 640.24K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 677.23K ).

Tazminat ve Kazançlar: Jacob şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Jacob Cohen (45 yo)

3yrs

Görev süresi

US$640,238

Tazminat

Mr. Jacob D. Cohen served as an Executive Vice President of Metiscan, Inc. since joining in August 2008 until July 2011 and also served as Executive Vice President of its subsidiary, Taptopia, Inc. He is E...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jacob Cohen	Co-Founder	3yrs	US$640.24k	30.35% $ 2.2m
Eugene Johnston	Chief Financial Officer	2yrs	US$56.50k	0.67% $ 48.8k
Amanda Hammer	Chief Operating Officer	1.4yrs	US$329.43k	0.59% $ 42.7k

2.0yrs

Ortalama Görev Süresi

45yo

Ortalama Yaş

Deneyimli Yönetim: MGRX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jacob Cohen	Co-Founder	3yrs	US$640.24k	30.35% $ 2.2m
Alexander Hamilton	Independent Director	2yrs	Veri yok	0.084% $ 6.1k
Lorraine D'Alessio	Independent Director	2yrs	Veri yok	0.59% $ 42.7k
Kenny Myers	Independent Director	2yrs	Veri yok	0.59% $ 42.7k
Brian Rudman	Chairman of the Advisory Board	1.8yrs	Veri yok	Veri yok
Aaron Andrew	Member of Advisory Board	1.4yrs	Veri yok	Veri yok
Douglas Christianson	Advisory Board Member	less than a year	Veri yok	Veri yok

2.0yrs

Ortalama Görev Süresi

45yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MGRX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Mangoceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Mangoceuticals, Inc.Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department

Independent Director notifies of intention to sell stock

Mangoceuticals, Inc., Annual General Meeting, Jun 17, 2024

High number of new and inexperienced directors

Mangoceuticals, Inc. Appoints Aaron Andrew to Its Advisory Board

Mangoceuticals, Inc. Appoints Amanda Hammer as New Chief Operating Officer

Recent updates

Mangoceuticals, Inc. Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions

Mangoceuticals, Inc. Launches 'Slim' Oral Semaglutide Weight Loss Treatment

Second quarter 2024 earnings released: US$0.092 loss per share (vs US$0.14 loss in 2Q 2023)

Mangoceuticals, Inc. Announces Successful Migration to Its Newly Developed DEA -Approved Telemedicine Operating System

MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts

Mangoceuticals, Inc.Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department

Independent Director notifies of intention to sell stock

Mangoceuticals, Inc. Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology

Mangorx to Introduce “Mojo” Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone Imbalances

New major risk - Shareholder dilution

First quarter 2024 earnings released: US$0.10 loss per share (vs US$0.23 loss in 1Q 2023)

Mangoceuticals, Inc., Annual General Meeting, Jun 17, 2024

Mangoceuticals, Inc. Provides Non-Compliance Update

New major risk - Shareholder dilution

New major risk - Financial position

Mangoceuticals, Inc. Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex® FDA Approved Oral Testosterone Replacement Therapy Treatment

Mangoceuticals, Inc. Accepting Pre Orders for its PRIME

High number of new and inexperienced directors

Mangoceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.2 million.

Mangoceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.2 million.

Mangoceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.2 million.

Mangoceuticals, Inc. to Introduce “Prime”, Powered by Kyzatrex® (Ciii Testosterone Undecanoate Capsules), for an FDA Approved Oral Testosterone Replacement Therapy (TRT) Product

Mangoceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3.6 million.

Mangoceuticals Expands its Men's Health Product Line with Compounded Hair Growth Treatment 'Grow' by MangoRx

Mangoceuticals, Inc. Receives an Expected Letter from Listing Qualifications Department of The Nasdaq Stock Market LLC

Mangoceuticals Receives Written Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with the Minimum Bid Price Requirements Set Forth in Nasdaq Listing Rule 5550(a)(2)

New major risk - Share price stability

New major risk - Market cap size

Mangoceuticals, Inc. Launches New Sildenafil Based Erectile Dysfunction Product with Signature Mango Flavor & Rapid Dissolve

Mangoceuticals, Inc. Announces Upcoming Launch of Its Sildenafil Based Mango Flavored Rapid Dissolve ED Product

Mangoceuticals, Inc. Appoints Aaron Andrew to Its Advisory Board

Mangoceuticals, Inc. Appoints Amanda Hammer as New Chief Operating Officer

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş